GlassScriptPhysician profile
Wade R Evans
NPI 1881350601
$8,820.03
in general payments reported to CMS, 2019-2025
51 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $2,309 · 2023: $3,700 · 2024: $2,438 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,360 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,359.50 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,559.24 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Abbvie INC. | $1,166.26 | 2022-2025 | |
| Biogen, INC. | $594.70 | 2022-2024 | Vumerity, Aduhelm, Tysabri |
| Neurocrine Biosciences, INC. | $457.81 | 2021-2024 | Ingrezza, Ongentys |
| Pfizer INC. | $323.29 | 2022-2025 | |
| Lundbeck LLC | $295.56 | 2022-2024 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $274.37 | 2022-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Novartis Pharmaceuticals Corporation | $253.45 | 2022-2024 | |
| Tanabe Pharma America, INC. | $222.16 | 2022-2024 | |
| Emd Serono, INC. | $206.18 | 2023-2024 | Mavenclad |
| Jazz Pharmaceuticals INC. | $199.48 | 2022-2024 | |
| Sk Life Science, INC. | $166.65 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $162.15 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $156.94 | 2022 | |
| Axsome Therapeutics, INC. | $156.44 | 2023-2024 | Auvelity, Sunosi |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $154.46 | 2022-2024 | Valtoco |
| Alkermes, INC. | $143.48 | 2022-2024 | Aristada, Lybalvi |
| Amneal Pharmaceuticals LLC | $138.35 | 2022-2024 | Rytary, Crexont |
| Eisai INC. | $134.74 | 2024 | |
| Argenx US, INC. | $133.26 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Supernus Pharmaceuticals, INC. | $132.77 | 2024 | Qelbree |
| Alexion Pharmaceuticals, INC. | $125.06 | 2021-2024 | Ultomiris |
| Kyowa Kirin, INC. | $111.44 | 2022-2023 | Nourianz |
| Ucb, INC. | $96.28 | 2022-2024 | Briviact |
| Vanda Pharmaceuticals INC. | $95.45 | 2022-2024 | Ponvory |
| Banner Life Sciences, LLC | $94.69 | 2021-2022 | |
| Amgen INC. | $89.18 | 2022-2024 | Uplizna, Aimovig |
| Corium, LLC | $85.23 | 2023 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.23 | 2023 | |
| Celgene Corporation | $81.49 | 2022-2024 | Zeposia |
| Genentech USA, INC. | $76.54 | 2023-2024 | Ocrevus Zunovo, Enspryng, Ocrevus |
| Genzyme Corporation | $75.39 | 2022-2023 | |
| Lilly USA, LLC | $71.24 | 2022-2024 | Emgality, Kisunla, Amyvid |
| Tg Therapeutics, INC. | $69.28 | 2023-2024 | |
| Grifols USA, LLC | $66.79 | 2022-2023 | Gamunex-C |
| Impel Pharmaceuticals INC. | $63.95 | 2023 | Trudhesa |
| Avion Pharmaceuticals | $58.92 | 2022-2023 | Dhivy |
| Sumitomo Pharma America, INC. | $53.72 | 2023-2024 | Aptiom |
| Merck Sharp & Dohme LLC | $46.17 | 2022-2025 | Lagevrio, Belsomra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $45.32 | 2022 | |
| Ironshore Pharmaceuticals INC. | $44.06 | 2022 | |
| Acadia Pharmaceuticals INC | $43.57 | 2024 | Nuplazid |
| Amylyx Pharmaceuticals, INC. | $37.74 | 2023 | Relyvrio |
| Averitas Pharma INC. | $31.78 | 2024 | Qutenza |
| Mallinckrodt Hospital Products INC. | $30.73 | 2021-2022 | |
| Genentech, INC. | $26.47 | 2023 | Ocrevus |
| Mdd US Operations, LLC | $20.99 | 2024 | Gocovri |
| Stryker Corporation | $18.61 | 2025 | Clottriever Bold Catheter |
| Sunovion Pharmaceuticals INC. | $15.90 | 2022 | |
| Currax Pharmaceuticals LLC | $14.91 | 2023 | Contrave, Onzetra Xsail |
| Indivior INC. | $14.16 | 2023 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wade Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.